Ask AI
ProCE Banner Activity

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists #2 

Slideset

Downloadable slides on anti-CD38–based frontline treatment strategies for transplant-ineligible multiple myeloma, including frailty assessment, quadruplet therapy trial data, toxicity management, and best practices related to supportive care.

Released: May 19, 2026

Share

Provided by

This program is aligned with specific priorities outlined in the National Strategy for Quality Improvement in Health Care, in particular, making care safer by reducing harm caused in the delivery of care, promoting the most effective prevention and treatment practices for the leading causes of mortality, and promoting effective communication and coordination of care.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM

Disclosure

Primary Author

James A. Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, GSK, Janssen.

Kelley L. Julian, PharmD, BCOP: consultant/advisor/speaker: GSK, Johnson & Johnson, Pfizer.